江苏康众数字医疗科技股份有限公司 股东大会议事规则 第一章 总则 第一条 为规范江苏康众数字医疗科技股份有限公司（以下简称"公司"） 的组织和行为，保证股东大会依法行使职权，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 中国证券监督管理委员会（以下简称"中国证监会"）发布的《上市公司股东大 会规则》等有关法律、法规和规范性文件以及《江苏康众数字医疗科技股份有限 公司章程》（以下简称"《公司章程》"）规定，特制定本规则。 第二条 公司召集、召开股东大会时适用本规则。 第二章 股东大会的职权 第三条 本规则对与会股东、公司全体董事、监事、高级管理人员、股东大 会的有关工作人员、列席股东大会的其他人员具有约束力。 第四条 公司董事会应严格遵守《公司法》及其他法律、法规关于召开股东 大会的各项规定，认真、按时组织好股东大会。公司全体董事对股东大会的正常 召开负有诚信勤勉的责任，不得阻碍股东大会依法履行职权。 第五条 股东大会是公司的最高权力机构，依法行使以下列职权： （一）决定公司的经营方针和投资计划； （二）选举和更换非由职工代表担任的董事、监事，决 ...

江苏康众数字医疗科技股份有限公司 监事会议事规则 第一章 总则 第一条 为进一步规范江苏康众数字医疗科技股份有限公司（以下简称"公 司"）监事会的议事方式和决策程序，促使监事和监事会有效地履行监督职责， 完善公司法人治理结构，根据《中华人民共和国公司法》、《中华人民共和国证券 法》等有关法律、法规和规范性文件的要求，以及《江苏康众数字医疗科技股份 有限公司章程》（以下简称"《公司章程》"）的有关规定，制订本规则。 第二条 监事会是公司的监督机构，向股东大会负责，对公司财务以及公司 董事、总经理和其他高级管理人员履行职责的合法合规性进行监督，维护公司及 股东的合法权益。 1 第二章 定期会议及临时会议 第三条 监事会会议分为定期会议和临时会议。 第四条 监事会定期会议应当每 6 个月至少召开 1 次。 第五条 监事可以提议召开临时监事会会议。 第三章 会议程序 第六条 监事会会议由监事会主席召集和主持；监事会主席不能履行职务或 者不履行职务的，由半数以上监事共同推举 1 名监事召集和主持。 第七条 召开监事会定期会议和临时会议，应当分别提前 10 日和 2 日将书 面会议通知，通过专人送出、邮递、传真、电子邮件 ...

江苏康众数字医疗科技股份有限公司 章 程 二〇二三年 八月 | 目 录 | | --- | | 第一章 | 总则 | 1 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 2 | | 第三章 | 股份 | 2 | | 第一节 | 股份发行 | 2 | | 第二节 | 股份增减和回购 | 3 | | 第三节 | 股份转让 | 5 | | 第四章 | 股东和股东大会 | 5 | | 第一节 | 股东 | 6 | | 第二节 | 股东大会的一般规定 | 8 | | 第三节 | 股东大会的召集 | 11 | | 第四节 | 股东大会的提案与通知 | 13 | | 第五节 | 股东大会的召开 | 14 | | 第六节 | 股东大会的表决和决议 | 17 | | 第五章 | 董事会 | 22 | | 第一节 | 董事 | 22 | | 第二节 | 董事会 | 25 | | 第六章 | 经理及其他高级管理人员 | 29 | | 第七章 | 监事会 | 32 | | 第一节 | 监事 | 32 | | 第二节 | 监事会 | 33 | | 第八章 | 财务会计制度、利润分配和审计 | 34 | ...

江苏康众数字医疗科技股份有限公司 控股子公司管理制度 第一章 总则 第一条 为促进江苏康众数字医疗科技股份有限公司（以下简称"公司"或 "本公司"）规范运作和健康发展，确保控股子公司规范、高效、有序运作，提 高公司整体资产运营质量，维护公司整体形象和投资者利益，根据《中华人民共 和国公司法》（以下简称"《公司法》"）《中华人民共和国证券法》《上海证券交易 所科创板股票上市规则》等法律、法规、规范性文件以及《江苏康众数字医疗科 技股份有限公司章程》（以下简称"《公司章程》"）规定，结合公司实际情况，特 制定本制度。 第二条 本制度所称"控股子公司"系指本公司持有其 50%以上的股份，或者 虽然持有其股份比例不足 50%、但能够实际控制的公司。 第三条 加强对控股子公司的管理，旨在建立有效的管控与整合机制，对本 公司的组织、资源、资产、投资等事项进行风险控制，提高本公司整体运作效率 和抵抗风险能力。 第四条 公司应依照本制度及相关内控制度的规定，及时、有效地对控股子 公司做好管理、指导、监督等工作。 第五条 控股子公司在本公司总体方针目标框架下，独立经营和自主管理， 合法有效地运作企业资产。 第二章 人事管理 第 ...

江苏康众数字医疗科技股份有限公司 内幕信息知情人登记管理制度 第一章 总则 第一条 为规范江苏康众数字医疗科技股份有限公司（以下简称"公司"） 的内幕信息管理，维护信息披露的公平原则，完善内、外部信息知情人管理事务， 避免及防范内幕信息知情人滥用知情权，进行内幕交易，根据《中华人民共和国 证券法》《上市公司信息披露管理办法》《上市公司监管指引第 5 号——上市公司 内幕信息知情人登记管理制度》和《上海证券交易所科创板股票上市规则》等法 律、法规、规章和规范性文件，以及《江苏康众数字医疗科技股份有限公司章程》 （以下简称"《公司章程》"）《江苏康众数字医疗科技股份有限公司信息披露 管理制度》的规定，制定本制度。 第二条 本制度适用于公司各部门、分公司、控股（包括全资，下同）子公 司以及本公司能够实施重大影响的参股公司。 （三）公司订立重要合同、提供重大担保或者从事关联交易，可能对公司的 资产、负债、权益和经营成果产生重要影响； （四）公司发生重大债务和未能清偿到期重大债务的违约情况； （五）公司发生重大亏损或者重大损失； 第四条 公司董事会是内幕信息的管理机构，董事会保证内幕信息知情人档 案真实、准确和完整，董 ...

证券代码：688607 证券简称：康众医疗 公告编号：2023-028 持股 5%以上股东减持股份进展公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，江苏康众数字医疗科技股份有限公司（以下简称"公 司"或"康众医疗"）股东畅城有限公司即 Matrix Future Limited（以下简称 "畅城"）持有康众医疗股份 8,239,476 股，占公司总股本的 9.35%；霍尔果斯 君联承宇创业投资有限公司（以下简称"君联承宇"）持有康众医疗股份 3,213,645 股，占公司总股本的 3.65%。畅城与君联承宇是一致行动人，所持股 份均为公司 IPO 前取得股份，该部分股份于 2022 年 2 月 7 日起限售期届满并上 市流通。 减持计划的进展情况 2023 年 4 月 18 日，公司披露了《康众医疗持股 5%以上股东减持股份计划公 告》（2023-007），畅城、君联承宇拟通过集中竞价及大宗交易方式合计减持不 超过 5,287,700 股（若计划 ...

Financial Performance - The company reported no cash dividends, stock bonuses, or capital reserve transfers for the 2022 profit distribution plan[5]. - The company has not achieved profitability since its listing[4]. - The company reported a revenue of ¥204,571,186.09 in 2022, a decrease of 40.18% compared to the previous year[21]. - The net profit attributable to shareholders was -¥5,623,874.72, down 106.61% year-on-year, while the net profit excluding non-recurring gains and losses was -¥21,196,323.74, a decline of 128.82%[23]. - The net cash flow from operating activities was -¥32,790,648.20, representing a 204.00% decrease from the previous year[24]. - Basic and diluted earnings per share were both -¥0.06, a drop of 106.06% compared to the previous year[24]. - The company achieved a main business revenue of 197,395,828.81 RMB, a year-on-year decrease of 39.83%, with medical revenue down 26.36% and industrial safety inspection revenue down 74.65%[104]. - The gross profit margin for the overall main business was 36.51%, a decrease of 11.30 percentage points compared to the previous year[106]. - Domestic revenue decreased by 35.29% to 96,597,020.60 RMB, while overseas revenue decreased by 43.61% to 100,798,808.21 RMB[106]. - The company's cash and cash equivalents decreased by 44.23%, amounting to ¥198,253,632.14 from ¥355,514,192.05 in the previous year[129]. Research and Development - The company increased its R&D investment to 21.76% of revenue, up 12.30 percentage points from the previous year[22]. - Research and development expenses for the year reached CNY 44,523,700, representing a year-on-year increase of 37.56%[34]. - The R&D team includes 4 PhD holders, 30 Master's degree holders, and 41 Bachelor's degree holders, reflecting a strong educational background[77]. - The company is focusing on developing an intelligent DRIC system, which includes real-time monitoring of X-ray source dosage and AI-assisted positioning, with plans for future investment in this technology[78]. - The company is actively developing new products, including wireless high-speed dynamic flat panel detectors and electronic materials for industrial applications, to enhance market presence[42]. - The company has developed a comprehensive range of digital X-ray flat panel detector products, covering major application areas including mammography, dynamic fluoroscopy, radiation therapy, and dental 3D imaging[82]. Market and Competition - The company faced intensified market competition and a decline in high-value product sales, impacting revenue and profitability[23]. - The company aims to enhance customer satisfaction by promoting a combination of flat panel detectors with key components such as tubes and high-voltage generators[35]. - The company is focusing on differentiated competition by investing in niche application areas of flat panel detectors, as the market concentration is expected to increase and competition intensifies[69]. - The global market for digital X-ray imaging systems is expected to expand significantly due to increasing replacement demand for outdated CR equipment and supportive national policies for DR technology development[65]. - The ongoing consolidation in the digital X-ray flat panel detector industry is expected to further increase market concentration, with major players accelerating mergers and acquisitions to enhance competitive advantages[67]. Governance and Management - The company received a standard unqualified audit report from its accounting firm[5]. - The company’s financial report is guaranteed to be true, accurate, and complete by its responsible personnel[5]. - The company’s board of directors and supervisory board members were all present at the board meeting[5]. - The company has established a governance structure that includes a strategic committee, nomination committee, compensation and assessment committee, and audit committee[155]. - The company emphasizes transparency and actively engages with investors, adhering to information disclosure obligations[159]. Strategic Initiatives - The company plans to enhance product competitiveness through increased R&D spending and operational management costs[23]. - The company aims to promote its global business strategy despite current market challenges[23]. - The company has established new subsidiaries in Singapore and South Korea, as well as an office in Europe, to enhance its international marketing and service network[36]. - The company is committed to cost optimization through various strategies, including enhancing production efficiency and upgrading core processes[38]. - The company plans to expand its overseas sales channels and improve service areas to increase market share in regions such as the US, India, and Europe[48]. Risks and Challenges - The company has detailed potential risks in its operations, which can be found in the "Management Discussion and Analysis" section[4]. - The company is subject to forward-looking statement risks, which do not constitute substantial commitments to investors[6]. - The company faces risks from reduced customer order demand and intensified market competition, impacting future performance[96]. - The company is exposed to foreign exchange risks due to its international operations, which could impact sales performance[98]. Employee and Compensation - The total number of employees in the parent company and major subsidiaries is 255, with 197 in the parent company and 58 in subsidiaries[189]. - The employee composition includes 73 production staff, 38 sales personnel, 78 technical staff, 15 finance staff, and 51 administrative staff[189]. - The company emphasizes a fair and performance-based compensation mechanism to motivate employees[190]. - Total compensation for all directors, supervisors, and senior management was RMB 4.3529 million at the end of the reporting period[175].

关于参加 2022 年度医疗设备专场集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 证券代码：688607 证券简称：康众医疗 公告编号：2023-024 江苏康众数字医疗科技股份有限公司 江苏康众数字医疗科技股份有限公司（以下简称"公司"）已于 2023 年 4 月 28 日在上海证券交易所网站（www.sse.com.cn）披露了公司《2022 年年度报 告》，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状况、 发展理念，公司参与了由上交所主办的 2022 年度医疗设备专场集体业绩说明会， 此次活动将采用视频和网络文字互动的方式举行，投资者可登录上海证券交易所 上证路演中心（http://roadshow.sseinfo.com/）参与线上互动交流。 一、说明会类型 本次投资者说明会以视频和网络文字互动形式召开，公司将针对 2022 年度 的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允 许的范围内就投资者普遍关注的问题进行回答。 二、说明会 ...

2022年年度报告 公司代码：688607 公司简称：康众医疗 江苏康众数字医疗科技股份有限公司 2022 年年度报告 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 50,118,994.79, representing a year-on-year increase of 31.58%[5] - The net profit attributable to shareholders was a loss of CNY 6,696,810.56, with a basic earnings per share of -0.08 yuan[5][6] - The company reported a net loss for Q1 2023, with total costs exceeding total revenue, indicating challenges in managing operational expenses[17] - The net profit for Q1 2023 was -6,670,634.06 RMB, compared to -7,232,998.53 RMB in Q1 2022, showing an improvement of approximately 7.8%[18] - The company reported a comprehensive loss of -7,755,168.80 RMB in Q1 2023, compared to -7,035,964.29 RMB in Q1 2022, indicating a decline of about 10.2%[19] Assets and Liabilities - Total assets at the end of the reporting period were CNY 900,801,285.14, a decrease of 0.21% compared to the end of the previous year[6] - Total assets amounted to RMB 900,801,285.14 as of March 31, 2023, slightly down from RMB 902,683,287.61 at the end of 2022[15] - Total liabilities increased to RMB 64,399,619.76 as of March 31, 2023, compared to RMB 58,526,453.43 at the end of 2022, reflecting an increase of 10.5%[16] - The company's equity attributable to shareholders decreased to RMB 836,421,291.38 as of March 31, 2023, down from RMB 844,202,636.68 at the end of 2022[16] Cash Flow - The company experienced a cash flow from operating activities loss of CNY 16,390,474.84[5] - Cash flow from operating activities showed a net outflow of -16,390,474.84 RMB in Q1 2023, an improvement from -18,775,283.32 RMB in Q1 2022[21] - The cash and cash equivalents at the end of Q1 2023 were 184,502,195.11 RMB, down from 216,869,303.99 RMB at the end of Q1 2022, a decrease of approximately 14.9%[23] - The investment activities resulted in a net cash outflow of -1,236,812.67 RMB in Q1 2023, compared to -118,933,422.09 RMB in Q1 2022, indicating a substantial reduction in cash outflow[23] Operating Costs and Expenses - Total operating costs for Q1 2023 were RMB 58,245,493.04, up from RMB 48,810,062.03 in Q1 2022, reflecting a year-over-year increase of 19.8%[17] - Research and development expenses totaled CNY 12,318,360.85, accounting for 24.58% of revenue, a decrease of 3.70 percentage points year-on-year[6] - Research and development expenses increased to 12,318,360.85 RMB in Q1 2023, up from 10,773,753.92 RMB in Q1 2022, reflecting a growth of approximately 14.3%[18] - The company incurred financial expenses of 1,236,356.97 RMB in Q1 2023, significantly higher than 88,717.06 RMB in Q1 2022, marking an increase of over 1,300%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period was 5,227[10] - Liu Jianqiang, an overseas natural person, held 14.54% of the shares, amounting to 12,810,000 shares[10] Strategic Focus - The company actively addressed internal and external uncertainties, leading to revenue growth through new products and technology implementations[8] - The company is focusing on expanding its market presence and enhancing product development to drive future growth[12]